Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047375 | 0.87 | MEN1 (0.64) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL8642675 | 0.79 | MEN1 (0.66) | KMT2AMEN1HSD17B10 | |
| SCHEMBL21850140 | 0.78 | KMT2A (0.49) | KMT2AMEN1HPGDCYP1A2ELANE | |
| SCHEMBL155369 | 0.72 | MEN1 (0.53) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL10937589 | 0.71 | CTSL (0.44) | KMT2AALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL10937584 | 0.71 | CTSL (0.44) | KMT2AALDH1A1SMN1; SMN2GAAKDM4E | |
| SCHEMBL25555697 | 0.70 | MEN1 (0.86) | KMT2AMEN1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL28004319 | 0.68 | ELANE (0.47) | KMT2AMEN1ALDH1A1FAAHHPGD | |
| SCHEMBL11931824 | 0.68 | CTSD (0.43) | KMT2AMEN1SMN1; SMN2HPGDMAPT | |
| SCHEMBL13551942 | 0.67 | ELANE (0.70) | KMT2AELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200176817-A1 | ELECTROLYTE AND BATTERY | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-3629411-A1 | ELECTROLYTE AND BATTERY | Contemporary Amperex Technology Co., Limited (CN) | 2020-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200176817-A1 | ELECTROLYTE AND BATTERY | ANO1, KCNN2, HCN2 | KMT2A 2566/4885MEN1 837/4885ALDH1A1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.